Cadus Pharmaceutical Corp., a subsidiary of ImClone SystemsInc., named Jeremy M. Levin president and chief executiveofficer. Both companies are based in New York. Prior to joiningCadus, Levin was vice president of corporate development at IGLaboratories Inc.
Boron Biologicals of Raleigh, N.C., named Charles R. Krausepresident and chief operating officer. Krause was group vicepresident with C.R. Bard Inc., a medical products company.
Belmac Corp. of Tampa, Fla., named Michael M. Harshbargerpresident and chief operating officer. He was managing directorof Healthcare Capital Group Inc., an investment bankingcompany.
Incstar Corp. of Stillwater, Minn., named Gerald Majewski vicepresident of research and development and John Buckholz vicepresident of new technology development. Majewski was thedirector of research and development at InstrumentationLaboratory; Buckholz was Incstar's director of marketing.
Robert M. Cohen was named director of regulatory affairs atGenelabs Technologies Inc. of Redwood City, Calif. Cohen wasdirector of regulatory and scientific affairs at ChemexPharmaceutical Inc.
Affinity Biotech Inc. of Boothwyn, Pa., named Susan T. Nielsendirector of pharmacology. She was a manager of theimmunology subdivision of Wyeth-Ayerst.
Diatech Inc. of Londonderry, N.H., named Larry R. Bush directorof therapeutic products. He was research leader incardiovascular research at Hoffmann-LaRoche.
(c) 1997 American Health Consultants. All rights reserved.